Stocks · News reference
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics shares fall as Phase 2 MOONLIGHT-1 depression trial fails primary endpoint. Partner J&J reviews additional trial data.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19
Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from $20 to $19.
Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Kestra Medical fell 8.6% after missing earnings estimates despite beating sales forecasts; several other stocks also declined premarket.
Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
Johnson & Johnson shares key clinical trial results for Tremfya in psoriatic arthritis and five-year Carvykti data in multiple myeloma.
Johnson & Johnson Announces That TREMFYA Met Primary And Major Secondary Endpoints Demonstrating Both Improvement In Axial Symptoms And Reduction In Inflammation By MRI Assessment In The Phase 4 STAR Study Evaluating Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement
STAR is the first and only dedicated randomized, double-blind, placebo-controlled study of its kind designed to prospectively evaluate an IL-23 inhibitor specifically in patients with axial involvement confirmed by
Johnson & Johnson Says 50% Of Patients Progression-Free At Five Years After Single Carvykti Infusion In Phase 2 Multiple Myeloma Trial